Takeda to Cut About 4,500 Jobs in FY2026 Amid Restructuring

• Takeda anticipates restructuring costs of around 170 billion yen in fiscal 2026, with lower amounts expected in the following two years
• The company reported revenue of 4.51 trillion yen during fiscal 2025, down 1.7% year-over-year
• The job cuts follow similar industry moves, including Novo Nordisk's September announcement to slash 9,000 jobs amid increased competition from Eli Lilly and copycat drugs

Takeda Pharmaceutical Restructuring Summary

Key Announcement:

Japan's Takeda Pharmaceutical plans to eliminate approximately 4,500 jobs in fiscal year 2026 as part of a major restructuring effort to centralize corporate functions and reduce costs.

Financial Targets:

• Expected annual savings: over 200 billion yen ($1.27 billion) by fiscal 2028
• Anticipated savings in FY2026: approximately 100 billion yen
• Restructuring costs for FY2026: around 170 billion yen, with lower amounts expected in subsequent years
• FY2025 revenue: 4.51 trillion yen, down 1.7% year-over-year

Strategic Context:

The restructuring continues Takeda's multi-year transformation following its $62 billion acquisition of Shire in 2019. While this deal expanded the company's global presence, it also added significant debt and operational complexity, necessitating ongoing cost optimization efforts.

Industry Context:

Takeda's workforce reduction follows a broader pharmaceutical industry trend. Danish competitor Novo Nordisk announced plans to cut 9,000 jobs in September to address growth challenges and competition from Eli Lilly and generic alternatives.

Pipeline Development:

Despite restructuring pressures, Takeda reported positive developments with its experimental treatment for primary immunodeficiency disease in mid-to-late stage studies. The company plans to seek regulatory approvals in the U.S., EU, and Japan in 2026.

Market Implications:

The significant cost-cutting measures signal Takeda's focus on improving operational efficiency and profitability amid revenue decline. The restructuring timeline and substantial savings targets suggest management is taking decisive action to address post-acquisition integration challenges while maintaining investment in key therapeutic areas.